Durvalumab as a maintenance therapy after a definitive chemoradiotherapy for a stage III non-small cell lung cancer - an interim analysis of the PACIFIC trial

被引：0
|
作者：
Kawecki, Maciej [1 ]
机构：
[1] Maria Sklodowska Curie Inst Oncol, Dept Radiotherapy & Oncol, Warsaw, Poland
来源：
ONCOLOGY IN CLINICAL PRACTICE | 2018年 / 14卷 / 03期
关键词：
D O I：
10.5603/OCP.2018.0023
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：167 / 170
页数：4
相关论文
共 50 条
  • [1] Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer
    Tomasini, Pascale
    Greillier, Laurent
    Boyer, Arnaud
    Jeanson, Arnaud
    Barlesi, Fabrice
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S1032 - S1036
  • [2] Interim Analysis of Neoadjuvant Chemoradiotherapy and Durvalumab for Potentially Resectable Stage III Non-Small Cell Lung Cancer (NSCLC)
    Hong, M. H.
    Ahn, B.
    Kim, H. R.
    Lim, S. M.
    Lee, S.
    Park, S. Y.
    Lee, C. Y.
    Lee, J. G.
    Kim, D. J.
    Lee, S. H.
    Yoon, H. I.
    Lee, C. G.
    Cho, J.
    Shim, H. S.
    Kim, T.
    Cho, B. C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S194 - S195
  • [3] Durvalumab After Chemoradiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
    Mooradian, Meghan J.
    Cai, Ling
    Wang, Alice
    Qiao, Yao
    Chander, Pratibha
    Whitaker, Ryan M.
    JAMA NETWORK OPEN, 2024, 7 (04) : e247542
  • [4] Pneumonitis After Chemoradiotherapy and Adjuvant Durvalumab in Stage III Non-Small Cell Lung Cancer
    Edwards, Donna M.
    Sankar, Kamya
    Alseri, Aaren
    Jiang, Ralph
    Schipper, Matthew
    Miller, Sean
    Dess, Kathryn
    Strohbehn, Garth W.
    Moghanaki, Drew
    Ramnath, Nithya
    Green, Michael D.
    Bryant, Alex K.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (04): : 963 - 970
  • [5] Durvalumab for Patients with Stage III EGFR-Mutated Non-Small Cell Lung Cancer Receiving Definitive Chemoradiotherapy
    Aredo, J. V.
    Hellyer, J. A.
    Neal, J. W.
    Padda, S. K.
    McCoach, C. E.
    Riess, J. W.
    Cabebe, E. C.
    Loo, B. W.
    Diehn, M.
    Wakelee, H. A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S15 - S15
  • [6] Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
    Kim, Young-Hak
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (10): : 989 - 990
  • [7] Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
    Antonia, S. J.
    Villegas, A.
    Daniel, D.
    Vicente, D.
    Murakami, S.
    Hui, R.
    Yokoi, T.
    Chiappori, A.
    Lee, K. H.
    de Wit, M.
    Cho, B. C.
    Bourhaba, M.
    Quantin, X.
    Tokito, T.
    Mekhail, T.
    Planchard, D.
    Kim, Y. -C.
    Karapetis, C. S.
    Hiret, S.
    Ostoros, G.
    Kubota, K.
    Gray, J. E.
    Paz-Ares, L.
    de Castro Carpeno, J.
    Wadsworth, C.
    Melillo, G.
    Jiang, H.
    Huang, Y.
    Dennis, P. A.
    Ozguroglu, M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20): : 1919 - 1929
  • [8] Durvalumab showed long and durable effects after chemoradiotherapy in stage III non-small cell lung cancer: results of the PACIFIC study
    Uemura, Takehiro
    Hida, Toyoaki
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S1108 - S1112
  • [9] Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer REPLY
    Antonia, Scott J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (10): : 990 - 990
  • [10] The impact of dosimetric parameters on pneumonitis in patients with stage III non-small cell lung cancer during maintenance treatment with durvalumab after chemoradiotherapy
    Vrankar, M.
    But-Hadzic, J.
    Stanic, K.
    Ciric, E.
    Jelercic, S.
    Vodusek, A. L.
    ANNALS OF ONCOLOGY, 2021, 32 : S944 - S944
12345